Attended by about 50 members, Part 2 of the “Precision Medicine Seminar Series” was an intensive panel discussion centered on discussing the opportunities and challenges of commercialization of precision medicine as well as its commercial applications.

At the panel discussion, topics such as where Hong Kong is in the development of precision medicine (from research to commercialization), how to facilitate its development progress, and how to gear up support for precision medicine’s commercial applications, etc., were discussed.

Dr. Alexander Chiu (Medical Director, Health and Employee Benefits of AXA Hong Kong and Macau), Dr. Ronald Li (Director & Professor, MWLC for Reparative Medicine, Karolinska Institute Hong Kong), Dr. Daniel Thurley (General Manager, Roche HK Limited), and Prof. Ian Wong (Head of Department of Pharmacology & Pharmacy, The University of Hong Kong) gave refined insights and comments from the perspectives of insurance, R&D, pharmaceutical and big data respectively.